ARCHIVES

Going private may allow US Oncology to restructure, respond to Medicare cuts; equity investment firm offers to purchase shares.

This article is from The Cancer Letter archive.

Vol. 30 No. 17 | April 23, 2004

Download PDF Visit The Full Archive

Related Articles

Retrospective Data Clean-up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”

March 8, 2002

Garb’s Questions, Answers About Cancer Program

December 5, 1980

Expert Review Of ImClone Protocol Concludes C225 Approval Unlikely.

February 15, 2002

ODAC Discussion: NCI’s Richard Simon Cautions About Rules Of Thumb

January 30, 2009

Micafungin Bests Fluconazole In Phase III Antifungal Trial

November 29, 2002

Gardasil Approved To Prevent Vulvar And Vaginal Cancers

September 26, 2008